Bionor Pharma develops universal influenza vaccine

Washington, 22.11.2011 - Bionor Pharma’s Universal Influenza Vaccine, Vacc-Flu, Targets Regions Shared by all Influenza A Strains; Reduces Serious Flu Symptoms by 25 Percent Over Standard Flu Vaccine in Animal Study.

In conjunction with the company’s presentation at the Influenza Congress in Arlington, Washington on Nov 10th , Bionor Pharma released the notification “Bionor Pharma ASA utvikler universell influensavaksine” to Oslo Stock Exchange and the company's website.

Click here to open the press release in the English version of the notification, that gives somewhat more detailed background information.